Skip to main content
Top
Published in: Diabetologia 2/2012

01-02-2012 | Article

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

Authors: I. Vermeulen, I. Weets, O. Costa, M. Asanghanwa, K. Verhaeghen, K. Decochez, J. Ruige, K. Casteels, J. Wenzlau, J. C. Hutton, D. G. Pipeleers, F. K. Gorus, the Belgian Diabetes Registry

Published in: Diabetologia | Issue 2/2012

Login to get access

Abstract

Aims/hypothesis

The appearance of autoantibodies (Abs) before diabetes onset has mainly been studied in young children. However, most patients develop type 1 diabetes after the age of 15 years. In first-degree relatives aged under 40 years, we investigated the frequency of seroconversion to (persistent) Ab positivity, progression to diabetes and baseline characteristics of seroconverters according to age.

Methods

Abs against insulin (IAA), glutamate decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured during follow-up of 7,170 first-degree relatives.

Results

We identified 379 (5.3%) relatives with positivity for IAA, GADA, IA-2A and/or ZnT8A (Ab+) at first sampling and 224 (3.1%) at a later time point. Most seroconversions occurred after the age of 10 years (63%). During follow-up, Abs persisted more often in relatives initially Ab+ (76%) than in seroconverters (53%; p < 0.001). In both groups diabetes developed at a similar pace and almost exclusively with Ab persistence (136 of 139 prediabetic individuals). For both groups, progression was more rapid if Abs appeared before the age of 10 years. Baseline characteristics at seroconversion did not vary significantly according to age.

Conclusions/interpretation

Seroconversion to (persistent) Ab+ occurs regardless of age. Although the progression rate to diabetes is higher under age 10 years, later seroconverters (up to age 40 years) have similar characteristics when compared with age-matched initially Ab+ relatives and generate an important minority of prediabetic relatives, warranting their identification and, eventually, enrolment in prevention trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Leslie RD, Delli Castelli M (2004) Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53:3033–3040PubMedCrossRef Leslie RD, Delli Castelli M (2004) Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53:3033–3040PubMedCrossRef
2.
go back to reference Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMedCrossRef Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMedCrossRef
3.
go back to reference Gorus FK (1997) Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 13:247–274PubMedCrossRef Gorus FK (1997) Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 13:247–274PubMedCrossRef
4.
go back to reference Skyler JS, Ricordi C (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 60:1–8PubMedCrossRef Skyler JS, Ricordi C (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 60:1–8PubMedCrossRef
5.
go back to reference Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRef Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRef
6.
go back to reference Gorus FK, Pipeleers DG (2001) Prospects for predicting and stopping the development of type 1 of diabetes. The Belgian Diabetes Registry. Best Pract Res Clin Endocrinol Metab 15:371–389PubMedCrossRef Gorus FK, Pipeleers DG (2001) Prospects for predicting and stopping the development of type 1 of diabetes. The Belgian Diabetes Registry. Best Pract Res Clin Endocrinol Metab 15:371–389PubMedCrossRef
7.
go back to reference Vandewalle CL, Coeckelberghs MI, de Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 20:1556–1561PubMedCrossRef Vandewalle CL, Coeckelberghs MI, de Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 20:1556–1561PubMedCrossRef
8.
go back to reference Kyvik K, Nyström L, Gorus F et al (2004) The epidemiology of type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 47:377–384PubMedCrossRef Kyvik K, Nyström L, Gorus F et al (2004) The epidemiology of type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 47:377–384PubMedCrossRef
9.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef
10.
go back to reference Kimpimäki T, Kupila A, Hämäläinen A-M et al (2001) The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish type 1 prediction and prevention study. J Clin Endocrinol Metab 86:4782–4788PubMedCrossRef Kimpimäki T, Kupila A, Hämäläinen A-M et al (2001) The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish type 1 prediction and prevention study. J Clin Endocrinol Metab 86:4782–4788PubMedCrossRef
11.
go back to reference Rewers M, Norris JM, Eisenbarth GS et al (1996) Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 9:405–410PubMedCrossRef Rewers M, Norris JM, Eisenbarth GS et al (1996) Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 9:405–410PubMedCrossRef
12.
go back to reference Carmichael SK, Johnson SB, Baughcum A et al (2003) Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 5:77–83PubMedCrossRef Carmichael SK, Johnson SB, Baughcum A et al (2003) Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 5:77–83PubMedCrossRef
13.
go back to reference TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1–13CrossRef TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1–13CrossRef
14.
go back to reference Knip M, Korhonen S, Kulmala P et al (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206–1212PubMedCrossRef Knip M, Korhonen S, Kulmala P et al (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206–1212PubMedCrossRef
15.
go back to reference Simell O, Winter WE, Schatz D (2010) Enhancing the understanding of pre-type 1 diabetes in the general population. Diabetes Care 33:1403–1405PubMedCrossRef Simell O, Winter WE, Schatz D (2010) Enhancing the understanding of pre-type 1 diabetes in the general population. Diabetes Care 33:1403–1405PubMedCrossRef
16.
go back to reference De Grijse J, Asanghanwa M, Nouthe B et al (2010) Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53:517–524PubMedCrossRef De Grijse J, Asanghanwa M, Nouthe B et al (2010) Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53:517–524PubMedCrossRef
17.
go back to reference Truyen I, de Pauw P, Jørgensen P et al (2005) Proinsulin levels and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48:2322–2329PubMedCrossRef Truyen I, de Pauw P, Jørgensen P et al (2005) Proinsulin levels and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48:2322–2329PubMedCrossRef
18.
go back to reference Van der Auwera BJ, Schuit FC, Weets I et al (2002) Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for further prevention studies. The Belgian Diabetes Registry. Hum Immunol 63:40–50PubMedCrossRef Van der Auwera BJ, Schuit FC, Weets I et al (2002) Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for further prevention studies. The Belgian Diabetes Registry. Hum Immunol 63:40–50PubMedCrossRef
19.
go back to reference Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045PubMedCrossRef Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045PubMedCrossRef
20.
go back to reference Achenbach P, Bonifacio E, Koczwara K, Ziegler A (2005) Natural history of type 1 diabetes. Diabetes 53(Suppl 2):S25–S31CrossRef Achenbach P, Bonifacio E, Koczwara K, Ziegler A (2005) Natural history of type 1 diabetes. Diabetes 53(Suppl 2):S25–S31CrossRef
21.
go back to reference Jasinski JM, Eisenbarth GS (2005) Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 12:181–186PubMedCrossRef Jasinski JM, Eisenbarth GS (2005) Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 12:181–186PubMedCrossRef
22.
go back to reference Bingley PJ (2010) Clinical application of diabetic antibody testing. J Clin Endocrinol Metab 95:25–33PubMedCrossRef Bingley PJ (2010) Clinical application of diabetic antibody testing. J Clin Endocrinol Metab 95:25–33PubMedCrossRef
23.
go back to reference Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW (2009) Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 9:105–112PubMedCrossRef Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW (2009) Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 9:105–112PubMedCrossRef
24.
go back to reference Myers MA, Rabin DU, Rowley MJ (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44:1290–1295PubMedCrossRef Myers MA, Rabin DU, Rowley MJ (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44:1290–1295PubMedCrossRef
25.
go back to reference Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef
26.
go back to reference Savola K, Läärä E, Vähäsalo P et al (2001) Dynamic pattern of disease-associated autoantibodies in siblings of children with type 1 diabetes. Diabetes 50:2625–2632PubMedCrossRef Savola K, Läärä E, Vähäsalo P et al (2001) Dynamic pattern of disease-associated autoantibodies in siblings of children with type 1 diabetes. Diabetes 50:2625–2632PubMedCrossRef
27.
go back to reference Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef
28.
go back to reference Gorus FK, Vandewalle CL, Dorchy H, van Crombrugge P, Schuit FC, Pipeleers DG (1994) Influence of age on the associations among insulin autoantibodies, islet cell antibodies, and HLA DAQ1*0301-DQB1*0302 in siblings of patients with type 1 (insulin-dependent) diabetes mellitus. Belgian Diabetes Registry. J Clin Endocrinol Metab 36:1155–1162 Gorus FK, Vandewalle CL, Dorchy H, van Crombrugge P, Schuit FC, Pipeleers DG (1994) Influence of age on the associations among insulin autoantibodies, islet cell antibodies, and HLA DAQ1*0301-DQB1*0302 in siblings of patients with type 1 (insulin-dependent) diabetes mellitus. Belgian Diabetes Registry. J Clin Endocrinol Metab 36:1155–1162
29.
go back to reference Yu J, Yu L, Bugawan TL et al (2000) Transient antiislet autoantibodies: infrequent occurrence and lack of association with “genetic” risk factors. J Clin Endocrinol Metab 85:2421–2428PubMedCrossRef Yu J, Yu L, Bugawan TL et al (2000) Transient antiislet autoantibodies: infrequent occurrence and lack of association with “genetic” risk factors. J Clin Endocrinol Metab 85:2421–2428PubMedCrossRef
30.
go back to reference Truyen I, de Grijse J, Weets I et al (2007) Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clin Exp Immunol 149:243–250PubMedCrossRef Truyen I, de Grijse J, Weets I et al (2007) Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clin Exp Immunol 149:243–250PubMedCrossRef
31.
go back to reference von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7:988–994CrossRef von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7:988–994CrossRef
32.
go back to reference Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies: a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41:424–429PubMedCrossRef Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies: a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41:424–429PubMedCrossRef
33.
go back to reference Decochez K, de Leeuw I, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. Diabetologia 45:1658–1666PubMedCrossRef Decochez K, de Leeuw I, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. Diabetologia 45:1658–1666PubMedCrossRef
34.
go back to reference Pihoker C, Gilliam LK, Hampe CS, Lernmark Å (2005) Autoantibodies in diabetes. Diabetes 54(Suppl 2):S52–S61PubMedCrossRef Pihoker C, Gilliam LK, Hampe CS, Lernmark Å (2005) Autoantibodies in diabetes. Diabetes 54(Suppl 2):S52–S61PubMedCrossRef
35.
go back to reference Achenbach P, Warncke K, Reiter J et al (2006) Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49:2969–2976PubMedCrossRef Achenbach P, Warncke K, Reiter J et al (2006) Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49:2969–2976PubMedCrossRef
36.
go back to reference Vehik K, Haller MJ, Beam CA et al (2011) Islet autoantibody seroconversion in the DPT-1 study. Diabetes Care 34:358–362PubMedCrossRef Vehik K, Haller MJ, Beam CA et al (2011) Islet autoantibody seroconversion in the DPT-1 study. Diabetes Care 34:358–362PubMedCrossRef
37.
go back to reference Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet natural history study. Diabetes Care 34:1897–1901PubMedCrossRef Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet natural history study. Diabetes Care 34:1897–1901PubMedCrossRef
38.
go back to reference Dahlquist G, Mustonen LR (1995) Clinical onset characteristics of familial versus nonfamilial cases in a large population-based cohort of childhood-onset diabetes patients. Diabetes Care 18:852–854PubMedCrossRef Dahlquist G, Mustonen LR (1995) Clinical onset characteristics of familial versus nonfamilial cases in a large population-based cohort of childhood-onset diabetes patients. Diabetes Care 18:852–854PubMedCrossRef
39.
go back to reference Veijola R, Reijonen H, Vähäsalo P et al (1996) HLA-DQ B1-defined genetic susceptibility, beta cell autoimmunity and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Invest 96:2489–2495CrossRef Veijola R, Reijonen H, Vähäsalo P et al (1996) HLA-DQ B1-defined genetic susceptibility, beta cell autoimmunity and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Invest 96:2489–2495CrossRef
Metadata
Title
An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age
Authors
I. Vermeulen
I. Weets
O. Costa
M. Asanghanwa
K. Verhaeghen
K. Decochez
J. Ruige
K. Casteels
J. Wenzlau
J. C. Hutton
D. G. Pipeleers
F. K. Gorus
the Belgian Diabetes Registry
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2376-1

Other articles of this Issue 2/2012

Diabetologia 2/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.